Dr Reddy's launches anti-fungal ointment in the US

Image
Press Trust of India New Delhi
Last Updated : Dec 05 2016 | 11:48 AM IST
Dr Reddy's Laboratories Ltd today announced the launch of anti-fungal ointment nystatin and triamcinolone acetonide in the US market.
In a BSE filing, Dr Reddy's Laboratories Ltd said, "It has launched nystatin and triamcinolone acetonide cream USP, in the United States market, approved by the US Food and Drug Administration (USFDA)."
The product is the generic equivalent of nystatin and triamcinolone acetonide cream, USP 1,00,000 units/g-0.1 per cent manufactured by Taro Pharmaceuticals USA Inc, it added.
Quoting IMS Health sales data, Dr Reddy's Laboratories said that for the 12-month period ending October 2016, the generic had US sales of around USD 119 million.
Dr Reddy's Laboratories' shares today were trading at Rs 3,178.70 in the morning trade on the BSE, down 0.03 per cent.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 05 2016 | 11:48 AM IST

Next Story